Sequentscientific · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Analyst questioned management on Trump-era pharma tariffs and Biocaut Act; Dr. Hari acknowledged ~17-18% US exposure but expressed more opportunity than risk given strong regulatory audit track record (5 audits in 12-15 months, all VAI/no 483).
Sequential gross margin declined QoQ despite YoY improvement due to less favorable product mix in API. Management acknowledged some quarters may see swings between 48-49% before sustaining upward trajectory.
Management declined to break out companion animal financials despite direct analyst question, citing ~5% of total business. This limits visibility into higher-margin segment performance and growth trajectory.
CDMO business buildout has 12-18 month timeline with team building still in progress. Management specifically said 'I don't want to just come up CDM just few things' indicating early-stage nature of this growth lever.
